Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Racemethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 8/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 7/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 7/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 7/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextromethorphan SCHEMBL29949 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL503864 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL248575 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL22722074 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL12091342 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levomethorphan SCHEMBL29950 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL7380035 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20808854 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20809259 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL21095577 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067608-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | AVANIR PHARMACEUTICALS INC (US) | 2024-02-29 | — | — | US | disclosed |
| EP-1744733-B1 | SOFTGEL ENCAPSULATED PHARMACEUTICAL COMPOSITIONS COMPRISING CONCENTRATED ACTIVE INGREDIENTS | PROCTER & GAMBLE (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9801400-B2 | Natural honey-containing compositions and method of preparation | THE PROCTER & GAMBLE COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150313892-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN ASSOCIATED WITH DYSMENORRHEA | TRINITY LAB INC (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150272173-A1 | Natural Honey-Containing Composition And Method Of Preparation | PROCTER & GAMBLE (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | UPSHER-SMITH LABORATORIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | UPSHER-SMITH LABORATORIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8026252-B2 | Large substituent, non-phenolic opioids and methods of use thereof | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090247562-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090017165-A1 | Natural Honey-Containing Compositions And Method Of Preparation | THE PROCTER & GAMBLE COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20040247646-A1 | Rapidly dissolving edible film compositions with improved film strength and stability | THE PROCTER & GAMBLE COMPANY | 2004-12-09 | — | — | US | disclosed |
| WO-2004089336-A2 | DRUG DELIVERY SYSTEMS COMPRISING AN ENCAPSULATED ACTIVE INGREDIENT | THE PROCTER & GAMBLE COMPANY (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040202698-A1 | Drug delivery systems comprising an encapsulated active ingredient | THE PROCTER & GAMBLE COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040162273-A1 | Powder pharmaceutical compositions | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-19 | — | — | US | disclosed |
| WO-2004066978-A1 | POWDER PHARMACEUTICAL COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20030139437-A1 | COMPOSITIONS HAVING IMPROVED DELIVERY OF ACTIVES | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| US-20030118613-A1 | COMPOSITIONS HAVING IMPROVED DELIVERY OF ACTIVES | DOBROZSI DOUGLAS JOSEPH (US) | 2003-06-26 | — | — | US | disclosed |
| US-20020086878-A1 | COMPOSITIONS HAVING IMPROVED STABILITY | DOBROZSI DOUGLAS JOSEPH (US) | 2002-07-04 | — | — | US | disclosed |
| US-20020082307-A1 | COMPOSITIONS HAVING IMPROVED STABILITY | DOBROZSI DOUGLAS JOSEPH (US) | 2002-06-27 | — | — | US | disclosed |
| US-5196436-A | High speed, peroral, alkaline | THE PROCTER & GAMBLE COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247562-A1 | LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF | OPRK1, OPRM1, OPRD1 | GRIN2A 58/4885SIGMAR1 4/4885GRIN1 142/4885 |
| US-20240067608-A1 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20150182462-A1 | Opioid-Containing Oral Pharmaceutical Compositions and Methods | OPRK1, OPRM1, OPRL1 | GRIN2A 374/4885SIGMAR1 6/4885GRIN1 401/4885 |
| US-20150272173-A1 | Natural Honey-Containing Composition And Method Of Preparation | LCT, CMA1, MGAM | GRIN2A 4862/4885SIGMAR1 4562/4885GRIN1 4821/4885 |
| US-20040247646-A1 | Rapidly dissolving edible film compositions with improved film strength and stability | SMURF1, PUF60, TAS2R40 | GRIN2A 4366/4885SIGMAR1 3305/4885GRIN1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.